clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Abnormalities, Drug-Induced D000014 10 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Abscess D000038 13 associated lipids
Achlorhydria D000126 1 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Adenocarcinoma D000230 166 associated lipids
Angina Pectoris D000787 27 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Bacterial Infections D001424 21 associated lipids
Bacteriuria D001437 7 associated lipids
Barrett Esophagus D001471 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Body Weight D001835 333 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Bradycardia D001919 13 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bronchiectasis D001987 7 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Katayama Y et al. Neuroprotective effects of clarithromycin against neuronal damage in cerebral ischemia and in cultured neuronal cells after oxygen-glucose deprivation. 2017 Life Sci. pmid:27825902
Moj D et al. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens. 2017 AAPS J pmid:27822600
Akpinar Z et al. Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth. 2017 Arab J Gastroenterol pmid:28532623
Beckman E et al. A Novel Stool PCR Test for Helicobacter pylori May Predict Clarithromycin Resistance and Eradication of Infection at a High Rate. 2017 J. Clin. Microbiol. pmid:28515219
Kajihara Y et al. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. 2017 Scand. J. Gastroenterol. pmid:27806639
Yan J et al. Survey about the use of clarithromycin in an ENT outpatient department of a tertiary hospital. 2017 Eur Arch Otorhinolaryngol pmid:28508178
Shaulov A et al. Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy. 2017 Am. J. Hematol. pmid:27804150
DaCosta A et al. Outcomes associated with antibiotic regimens for treatment of Mycobacterium abscessus in cystic fibrosis patients. 2017 J. Cyst. Fibros. pmid:28495380
Malfertheiner P et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. 2017 Gut pmid:27707777
Sharifi R et al. Dietary PUFA Increase Apoptosis in Stomach of Patients with Dyspeptic Symptoms and Infected with H. pylori. 2017 Lipids pmid:28493185
Morimoto K et al. A Laboratory-based Analysis of Nontuberculous Mycobacterial Lung Disease in Japan from 2012 to 2013. 2017 Ann Am Thorac Soc pmid:27788025
Reddy AB and Reddy ND Development of Multiple-Unit Floating Drug Delivery System of Clarithromycin: Formulation, in vitro Dissolution by Modified Dissolution Apparatus, in vivo Radiographic Studies in Human Volunteers. 2017 Drug Res (Stuttg) pmid:28449156
Aktas AH and Saridag AM Liquid Chromatographic-Chemometric Techniques for the Simultaneous HPLC Determination of Lansoprazole, Amoxicillin and Clarithromycin in Commercial Preparation. 2017 J Chromatogr Sci pmid:28449104
Itskoviz D et al. Smoking increases the likelihood of Helicobacter pylori treatment failure. 2017 Dig Liver Dis pmid:28427781
Koštrun S et al. Around the macrolide - Impact of 3D structure of macrocycles on lipophilicity and cellular accumulation. 2017 Eur J Med Chem pmid:28410508
Wong AYS et al. Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis. 2017 Drug Saf pmid:28397186
Ivanová L et al. Estimation of amount of selected pharmaceuticals sorbed onto digested sludge from wastewater treatment plant Bratislava-Petržalka. 2017 Environ. Res. pmid:28183039
Giguère S et al. Antimicrobial Resistance in . 2017 Microbiol Spectr pmid:29052538
Giguère S Treatment of Infections Caused by Rhodococcus equi. 2017 Vet. Clin. North Am. Equine Pract. pmid:28161038
Berni E et al. Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. 2017 BMJ Open pmid:28115334
Yatera K et al. The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases. 2017 Respir Investig pmid:29153420
Lee MC et al. Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan. 2017 J. Antimicrob. Chemother. pmid:29091186
Costa S et al. Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection. 2017 Eur J Gastroenterol Hepatol pmid:28877088
Pryjma M et al. Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the Gene. 2017 Antimicrob. Agents Chemother. pmid:28874379
Takahashi C et al. Morphological study of efficacy of clarithromycin-loaded nanocarriers for treatment of biofilm infection disease. 2017 Med Mol Morphol pmid:27119723
Laidler N Cutaneous infection with paucibacillary treated successfully with a modified antituberculous drug regimen. 2017 BMJ Case Rep pmid:29275384
Lee JS et al. Implication of species change of Nontuberculous Mycobacteria during or after treatment. 2017 BMC Pulm Med pmid:29262802
Ruiter R et al. Helicobacter pylori resistance in the Netherlands: a growing problem? 2017 Neth J Med pmid:29219812
Tsay FW et al. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. 2017 Antimicrob. Agents Chemother. pmid:28807915
Oh ES et al. Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers. 2017 J Clin Pharm Ther pmid:28806472
Kuo YT et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. 2017 Lancet Gastroenterol Hepatol pmid:28781119
Ramas M et al. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. 2017 Gastroenterol Hepatol pmid:28780968
Painsi C and Lange-Asschenfeldt B Image Gallery: Pink papules within a tattoo linked to Mycobacterium chelonae infection. 2017 Br. J. Dermatol. pmid:28731256
Fremlin GA et al. Clarithromycin, rifampicin and fusidic acid triple combination therapy for chronic folliculocentric pustulosis of the scalp. 2017 Clin. Exp. Dermatol. pmid:28691163
Mougari F et al. Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. 2017 Antimicrob. Agents Chemother. pmid:27799212
Hu Y et al. Novel and Effective Therapeutic Regimens for in an Era of Increasing Antibiotic Resistance. 2017 Front Cell Infect Microbiol pmid:28529929
Jeong SH et al. Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections. 2017 Int. J. Infect. Dis. pmid:28522316
Kishida D et al. Intractable Cutaneous Nontuberculous Mycobacteriosis (Mycobacterium abscessus) during Treatment for Systemic Lupus Erythematosus. 2017 Intern. Med. pmid:28502947
Jung YS et al. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. 2017 Aliment. Pharmacol. Ther. pmid:28497487
Sharman MJ et al. Gastrokine mRNA expression in gastric tissue from dogs with helicobacter colonisation but without inflammatory change during treatment. 2017 Vet. Immunol. Immunopathol. pmid:28494926
O'Brien CR et al. Feline leprosy due to Candidatus 'Mycobacterium tarwinense':Further clinical and molecular characterisation of 15 previously reported cases and an additional 27 cases 2017 J. Feline Med. Surg. pmid:28438086
Tan B et al. Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. 2017 PLoS ONE pmid:28407007
Freyne B and Curtis N Mycobacterium gordonae Skin Infection in an Immunocompetent Child. 2017 Pediatr. Infect. Dis. J. pmid:28403059
Kristin F et al. Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin. 2017 Eur J Pharm Sci pmid:28179133
Chen D et al. Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. 2017 Antimicrob. Agents Chemother. pmid:28167563
Olesen JS et al. Mycobacterium chelonae hand infection after steroid injection in a patient with rheumatoid arthritis receiving long-term linezolid therapy. 2017 BMJ Case Rep pmid:28137898
Chang JY et al. Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication. 2017 BMC Gastroenterol pmid:28109257
Sasaoka Y et al. Neonatal apnea with Chlamydia pneumoniae infection. 2017 Pediatr Int pmid:28102626
Lapa GB et al. Two approaches to the use of benzo[c][1,2]oxaboroles as active fragments for synthetic transformation of clarithromycin. 2017 J Enzyme Inhib Med Chem pmid:28097898
Chen PY et al. Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. 2017 Aliment. Pharmacol. Ther. pmid:28074519